Riskpilot← Back to searchSign inGet full accessXELLIA PHARMACEUTICALS AS
ASActiveOrg 971135123Silurveien 2, 0380 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 199430 employees
Revenue 2024
NOK 83,1M
-3% vs 2023
EBITDA margin
16.1%
0% vs 2023
Equity ratio
90.5%
Financial strength
Net profit 2024
NOK 74,4M
+73% vs 2023
| Revenue | NOK 83,1M | -3% |
| EBITDA | NOK 13,4M | +0% |
| Net profit | NOK 74,4M | +73% |
| Total assets | NOK 781,3M | +7% |
| Equity | NOK 707,2M | +5% |
| Employees | 30 | — |
Legal name
XELLIA PHARMACEUTICALS AS
Org number
971135123
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16. mai 1994
Share capital
NOK 223 257 350
Employees
30 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og nestleder i fellesskap, eller styrets leder/nestleder og daglig leder i fellesskap, eller styrets leder/nestleder og to styremedlemmer i fellesskap, eller daglig leder sammen med to styremedlemmer.
Company purpose
Utvikling, tilberedning og forhandling av farmasøytiske aktivstoffer, ferdig legemidler og dyrehelsepreparater og andre produkter i den utstrekning styret bestemmer, samt deltagelse som aksjonær, lånegiver, garantist eller på annen måte i andre foretagender.
Address
Silurveien 2, 0380 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 81 520 | 73 253 | 88 993 | 85 872 | 83 145 |
| Staff expenses | −51 377 | −46 025 | −54 333 | −51 413 | −52 115 |
| EBITDA | 11 244 | 10 530 | 13 346 | 13 362 | 13 358 |
| Depreciation & amort. | −5 980 | −6 242 | −6 396 | −6 380 | −6 068 |
| EBIT | 5 264 | 4 288 | 6 950 | 6 982 | 7 290 |
| Net financials | 7 815 | 14 388 | 45 147 | 43 627 | 78 946 |
| Profit before tax | 13 079 | 18 676 | 52 097 | 50 609 | 86 236 |
| Tax | −0 | −0 | −0 | 7 663 | 11 857 |
| Net profit | 13 079 | 18 676 | 52 097 | 42 946 | 74 379 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 619 813 | 626 110 | 680 840 | 732 234 | 781 317 |
| Equity | 586 757 | 606 370 | 658 544 | 674 435 | 707 205 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 28 044 | 15 901 | 18 698 | 54 428 | 71 226 |
| Total debt | 28 044 | 15 901 | 18 698 | 54 428 | 71 226 |
EBITDA margin
16.1%
This company
15.8%
Market median
+2% vs market
20202024
Equity ratio
90.5%
This company
38.2%
Market median
+137% vs market
20202024
Return on equity
10.5%
This company
18.4%
Market median
+43% vs market
20202024
Net profit margin
89.5%
This company
8.1%
Market median
+1005% vs market
20202024
Asset turnover
0.11×
This company
1.12×
Market median
-90% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
HO Deputy Member | Deputy Member | 2022 |
MK Chief Executive Officer | Chief Executive Officer | 2023 |
MS Deputy Member | Deputy Member | 2025 |
| Former (1) | ||
CC Chief Executive Officer | Chief Executive Officer | 2016 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
EB | Board of Directors | 2025 |
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Deputy Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2023 | |
| Former (4) | ||
| Board of Directors | 2022 – 2024 | |
| Deputy Chairman | 2020 – 2021 | |
| Board of Directors | 2022 – 2025 | |
| Chairman | 2022 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Otnortopco As
XELLIA PHARMACEUTICALS AS Board members of XELLIA PHARMACEUTICALS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helle Olsen | Deputy Member | 0 companies |
| Michael Kocher | Chief Executive Officer | 0 companies |
| Carl-Åke Carlsson | Chief Executive Officer | 0 companies |
| Marco Simon Petersen | Deputy Member | 0 companies |
| Frode Flem | Board of Directors | 0 companies |
| Mikkel Lyager Olsen | Deputy Chairman | 0 companies |
| Eva Blem | Board of Directors | 0 companies |
| Marianne Grøstad Nesje | Board of Directors | 0 companies |
| Anne Mette Nygård | Chairman | 0 companies |
| Bente Schmidt Nielsen | Board of Directors | 0 companies |
| Knut Danielsen | Chairman | 0 companies |
| Søren Hostrup | Deputy Chairman | 0 companies |
| Håvard Klemsdal | Board of Directors | 0 companies |
| Frode Aasen-Flem | Board of Directors | 0 companies |